Intestinal Failure, Short Gut Syndrome and Small Bowel Transplantation (R21)

The summary for the Intestinal Failure, Short Gut Syndrome and Small Bowel Transplantation (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Intestinal Failure, Short Gut Syndrome and Small Bowel Transplantation (R21): The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) seeks grant applications to study the pathogenesis, natural history, treatment and complications of intestinal failure and its therapies, including parenteral nutrition and small bowel transplantation. Intestinal failure, which is defined as reduced absorption of nutrients from the gastrointestinal tract resulting in the need for parenteral nutrition for survival, has many causes, including primary defects of intestinal epithelial absorption, motility disorders, and loss of large portions of the intestine due to surgical resection for congenital defects, necrotizing enterocolitis, ischemia, trauma, and inflammatory bowel disease. It is estimated that 20,000 individuals in the United States are supported by parenteral nutrition for intestinal failure and that the economic and quality of life burden for these patients is very high. A small fraction of these patients undergo small bowel transplantation, a treatment with significant morbidity, mortality, and high cost. Thus, new fundamental discoveries that lead to ways to prevent intestinal failure or its complications, to improve existing therapies, parenteral nutrition or small bowel transplantation, or to devise novel therapies, could lead to a significant improvement in quality of life and decreased cost of care for patients suffering from intestinal failure.